Developer docs
API playgroundTry for free, no card

Search company profiles

KVK Tech

Full company profile

uuid0005f7n

Namestring
KVK Tech
Legal namestring
KVK Tech, Inc.
Websiteurl
kvktech.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

KVK Tech, Inc. is a privately held specialty pharmaceutical manufacturer founded in 2004 and headquartered in Newtown, Pennsylvania. The company develops, manufactures, and markets FDA-approved generic medicines across multiple dosage forms — tablets, capsules, liquids, ointments/creams, nasals, ophthalmics, and (soon) injectables — and operates one branded-generic product, Lomaira (phentermine HCl USP 8 mg), positioned as a low-cost weight-loss alternative to branded competitors such as Qsymia, Belviq XR, and Contrave. All products are manufactured, packaged, and distributed in-house in the United States, an integrated model KVK cites as a key differentiator versus competitors reliant on offshore supply. The product portfolio spans therapeutic areas including weight management, allergy, cardiovascular, ophthalmology, neurology, urology, hepatology, nephrology, and anti-infectives.

The company monetizes its portfolio primarily through wholesale distribution to the nation's largest pharmacy chains, wholesalers, and distributors, supplemented by patient assistance programs (the Lomaira 1-2-3 Savings Program at $5–$15/month and the Lo-Cost Access Program at ≤50¢ per tablet) that drive retail pull-through. KVK also pursues contract development and manufacturing services — formulation, Chemistry, Manufacturing & Controls (CMC), and FDA submission readiness — through strategic partnerships such as Sen-Jam Pharmaceutical, where it holds exclusive U.S. manufacturing rights and an equity stake. International expansion is executed via licensing agreements (e.g., Productos Medix for Lomaira in Mexico). Under its Vision 2025 initiative, KVK is constructing a 250,000-square-foot sterile injectable plant in Langhorne, PA and acquired a 461,000-square-foot former Lockheed-Martin complex adjacent to its Newtown headquarters, materially expanding capacity and signaling entry into higher-value sterile injectables.

Short descriptiontext

KVK Tech is a privately held, Newtown, Pennsylvania-based specialty pharmaceutical manufacturer founded in 2004 that develops, manufactures, and distributes FDA-approved generic medicines and the branded-generic weight-loss product Lomaira domestically across multiple dosage forms and therapeutic areas.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersNewtown, United States
HQ citystring
Newtown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, FDA-approved medications, specialty pharmaceutical manufacturing, weight management drugs, contract pharmaceutical development
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Generic Pharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Generic Pharmaceutical Product Sales
TypeOne Time License
Description

KVK develops, manufactures, and markets FDA-approved generic pharmaceuticals, generating revenue through the sale of prescription generic medications to pharmacy chains, wholesalers, distributors, and healthcare providers. Revenue is driven by product portfolio breadth across multiple therapeutic areas and dosage forms.

kvktech.com
2Contract Manufacturing & Development Services
TypeLicensing Royalties
Description

KVK provides formulation development, CMC, and FDA submission readiness services to partner companies such as Sen-Jam Pharmaceutical, including exclusive manufacturing and distribution rights for the United States, generating service and licensing fees.

kvktech.com
3International Licensing & Royalties
TypeLicensing Royalties
Description

Licensing agreements with international partners such as Medix in Mexico for the manufacture, distribution, and marketing of Lomaira, generating milestone payments and ongoing royalties.

kvktech.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Others, Infrastructure
Pricing details3 tiers
1Lomaira 1-2-3 Savings Program — $5/1x daily, $10/2x daily, $15/3x daily
ModelUnit PricingBilling cadenceMonthly
Notes

The 1-2-3 program sets Lomaira pricing at $5 per month for patients taking once daily, $10 per month for twice daily, and $15 per month for three times daily. Available with a voucher and prescription. Limited time offer.

kvktech.com
2Lomaira Lo-Cost Access Program — no more than 50¢ per tablet
ModelUnit PricingBilling cadenceMonthly
Notes

Eligible patients pay no more than 50¢ per tablet for the duration of treatment through the Lo-Cost Access Program.

kvktech.com
3Lomaira no-expiration savings card — $43.50/month for 3 tablets/day
ModelUnit PricingBilling cadenceMonthly
Notes

Patients prescribed 3 tablets per day pay $43.50 per month through a no-expiration savings card. This compares to significantly higher costs for competing weight-loss treatments: Qsymia ($204.18), Belviq XR ($286.60), Contrave ($264.57).

kvktech.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Lomaira
Description

FDA-approved phentermine hydrochloride USP 8mg tablets for weight reduction, the company's flagship branded generic product.

kvktech.com
Core offering1 text field

KVK Tech is a specialty pharmaceutical company that develops, manufactures, and markets FDA-approved generic prescription medications and one branded product (Lomaira) across therapeutic areas including weight management, allergy, muscle relaxation, cardiovascular, and ophthalmology. The company operates fully integrated U.S.-based manufacturing facilities in Pennsylvania, producing oral solids (tablets, capsules), liquids, ointments/creams, nasals, ophthalmics, and injectables. It also provides formulation, CMC, and FDA submission readiness services to development partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Lomaira costs $43.50/month for 3 tablets/day vs. competing treatments: Qsymia ($204.18), Belviq XR ($286.60), Contrave ($264.57)
+1 more record
Product overview1 text field

KVK Tech is a specialty pharmaceutical manufacturer offering a portfolio of FDA-approved generic drugs and one branded product (Lomaira). The company manufactures all products in-house at their Pennsylvania facility, covering oral solids (tablets, capsules), oral suspensions, ophthalmic drops, and injectable solutions. The core branded product is Lomaira, an appetite suppressant for weight reduction. The generic portfolio includes medications across therapeutic categories: weight management (phentermine, benzphetamine, phendimetrazine), allergy (chlorpheniramine, promethazine, hydroxyzine), muscle relaxants (cyclobenzaprine), cardiovascular (betaxolol, isoproterenol), neurological/psychiatric (butalbital combinations), urological (oxybutynin), hepatology (ursodiol), nephrology (sodium polystyrene sulfonate), anti-infectives (atovaquone), immunosuppression (cyclosporine), and anti-inflammatory (indomethacin). The company positions itself on quality, affordability, and domestic manufacturing.

Product and service18 records
1Lomaira (phentermine hydrochloride USP) 8mg tablets, CIV
CategoryBranded weight management drug
Description

Prescription weight reduction medication containing phentermine hydrochloride, the most commonly prescribed drug for weight loss. The only strength of phentermine FDA-approved for use up to three times daily before meals, offering flexible dosing for personalized weight-loss treatment plans.

2Atovaquone Oral Suspension, USP 750 mg/5mL
CategoryGeneric anti-infective drug
Description

Prescription medication for treating Pneumocystis jiroveci pneumonia (PCP) in teenagers and adults with HIV, and for preventing immunocompromised patients from contracting this type of pneumonia.

3Betaxolol Tablets, USP
CategoryGeneric cardiovascular drug
Description

Beta-blocker medication for the treatment of hypertension, equivalent to brand Kerlone.

4Cyclobenzaprine HCl, USP
CategoryGeneric muscle relaxant
Description

Muscle relaxant medication for relieving muscle spasms, equivalent to brand Flexeril.

5Cyclosporine Emulsion Ophthalmic Drops 0.05%
CategoryAuthorized generic ophthalmic drug
Description

Authorized generic version of Restasis for treating dry eye disease, providing the same formulation as the brand-name product.

6Hydroxyzine HCl Tablets
CategoryGeneric antihistamine
Description

Antihistamine medication for anxiety relief and allergic conditions, equivalent to brand Atarax.

7Phentermine HCl
CategoryGeneric weight management drug
Description

Appetite suppressant medication available in tablet and capsule forms (15mg, 30mg, 37.5mg), equivalent to brand Adipex-P and Fastin.

8Phendimetrazine Tartrate Tablets
CategoryGeneric weight management drug
Description

Appetite suppressant medication for short-term weight reduction, available in yellow and blue formulations, equivalent to brands Bontril PDM and Plegine.

9Benzphetamine HCl Tablets
CategoryGeneric weight management drug
Description

Appetite suppressant medication for weight reduction, equivalent to brand Didrex.

10Butalbital-Acetaminophen-Caffeine Tablets
CategoryGeneric analgesic
Description

Combination analgesic medication for tension headaches, equivalent to brand Fioricet.

11Chlorphen-12 / Chlorpheniramine Maleate ER Tablets
CategoryGeneric antihistamine
Description

Extended-release antihistamine for allergy relief, equivalent to brand Chlor-Trimeton 12 Hour.

12Oxybutynin Chloride Tablets
CategoryGeneric urological drug
Description

Anticholinergic medication for overactive bladder, equivalent to brand Ditropan.

13Promethazine HCl Tablets
CategoryGeneric antihistamine
Description

Antihistamine and anti-nausea medication, equivalent to brand Phenergan.

14Indomethacin Extended Release Capsules
CategoryGeneric anti-inflammatory
Description

NSAID medication for pain, inflammation, and arthritis, equivalent to brand Indocin SR.

15Isoproterenol HCl Injection Solution
CategoryGeneric cardiovascular injectable
Description

Bronchodilator and cardiac stimulant injection, equivalent to brand Isuprel.

16Sodium Polystyrene Sulfonate (SPS)
CategoryGeneric nephrology drug
Description

Potassium-binding resin medication for treating hyperkalemia, available in powder form and unit dose, equivalent to brand Kayexalate.

17Ursodiol Capsules
CategoryGeneric hepatology drug
Description

Bile acid medication for treating gallstones and liver conditions, equivalent to brand Actigall.

18Contract Development, CMC and Manufacturing Services
CategoryContract pharmaceutical development and manufacturing
Description

Pharmaceutical formulation, CMC, and FDA submission readiness services offered to development partners, including exclusive U.S. manufacturing and distribution rights, as demonstrated through the Sen-Jam Pharmaceutical agreement.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeOthersAnnounced on2025-12-11
Description

TASK Clinical, a global contract research organization, partnered with Sen-Jam Pharmaceutical and will fund two-thirds of the upcoming Phase 3 clinical trial for SJP-001 in exchange for equity. KVK serves as Sen-Jam's corporate venture partner on this program.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-03-22
Description

Sen-Jam Pharmaceutical entered a strategic development, manufacturing, distribution, and license agreement with KVK Tech for an oral COVID-19 therapeutic. KVK provides formulation and Chemistry, Manufacturing & Controls (CMC) services while Sen-Jam completes Phase II clinical trials. KVK is making a strategic investment and will have exclusive Manufacturing and Distribution rights for the United States. KVK also serves as KVK's corporate venture partner handling formulation, CMC, and FDA submission readiness for SJP-001 (hangover-prevention therapeutic).

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2017-11-14
Description

KVK entered a strategic licensing agreement with Medix for the manufacture, distribution, and marketing of Lomaira (phentermine hydrochloride USP) 8mg tablets in Mexico. Medix, a leader in pharmaceutical obesity products in Mexico, plans to leverage its extensive physician network and portfolio of over 10 weight-loss products. The agreement includes milestone payments and royalties to KVK. Mexico has the second largest population with obesity in the world.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Lannett is a U.S.-based specialty generic pharmaceutical manufacturer with comparable portfolio breadth across multiple dosage forms and therapeutic categories, similar mid-market scale, and similar reliance on a broad generic portfolio for revenue.

TypeDirect peer
Description

Endo operates a specialty generics and branded generics business with overlapping therapeutic categories (pain, urology, ophthalmology) and a similar U.S. manufacturing footprint. Comparable in serving retail pharmacy chains and wholesalers through a generics-led model.

TypeDirect peer
Description

Upsher-Smith is a privately held U.S. specialty generics manufacturer of similar size and structure, with comparable FDA-approved generic portfolio and domestic manufacturing focus — a near-direct comparability on business model.

TypeDirect peer
Description

Amneal is a major U.S. generic pharmaceutical manufacturer with a broad portfolio spanning solid orals, injectables, and ophthalmics — directly comparable to KVK's dosage-form breadth and therapeutic categories.

TypeDirect peer
Description

Camber is a U.S. generics manufacturer specializing in oral solids and other dosage forms; was named alongside KVK in Stanford's methylphenidate quality study, indicating a directly comparable product portfolio and competitive positioning.

6Sandoz (Novartis)
TypeBroad incumbent
Description

Sandoz is one of the world's largest generic pharmaceutical manufacturers; identified alongside KVK in third-party quality rankings. A broader incumbent that competes across most of KVK's therapeutic categories but at vastly greater scale.

7Sun Pharmaceutical Industries
TypeBroad incumbent
Description

Sun Pharma is a global specialty generics leader; named alongside KVK in Stanford's methylphenidate quality study, signaling overlapping U.S. generic portfolios and directly competitive positioning.

TypeBroad incumbent
Description

Teva is the largest global generic manufacturer with broad U.S. presence across multiple dosage forms including sterile injectables; a broad incumbent that competes with KVK across most categories and is the dominant force shaping U.S. generic pricing dynamics.

TypeDirect peer
Description

Apotex is a major privately held Canadian-headquartered generic manufacturer with a significant U.S. commercial presence across solid orals and other dosage forms; comparable in business model and customer base to KVK.

TypeDirect peer
Description

Patriot Pharmaceuticals is a U.S. specialty generics company; named alongside KVK-TECH in the Stanford methylphenidate quality study, indicating a directly comparable generics portfolio in the U.S. market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

KVK Tech

Generic Pharmaceuticalskvktech.com

KVK Tech is a privately held, Newtown, Pennsylvania-based specialty pharmaceutical manufacturer founded in 2004 that develops, manufactures, and distributes FDA-approved generic medicines and the branded-generic weight-loss product Lomaira domestically across multiple dosage forms and therapeutic areas.

What KVK Tech does

KVK Tech, Inc. is a privately held specialty pharmaceutical manufacturer founded in 2004 and headquartered in Newtown, Pennsylvania. The company develops, manufactures, and markets FDA-approved generic medicines across multiple dosage forms — tablets, capsules, liquids, ointments/creams, nasals, ophthalmics, and (soon) injectables — and operates one branded-generic product, Lomaira (phentermine HCl USP 8 mg), positioned as a low-cost weight-loss alternative to branded competitors such as Qsymia, Belviq XR, and Contrave. All products are manufactured, packaged, and distributed in-house in the United States, an integrated model KVK cites as a key differentiator versus competitors reliant on offshore supply. The product portfolio spans therapeutic areas including weight management, allergy, cardiovascular, ophthalmology, neurology, urology, hepatology, nephrology, and anti-infectives.

The company monetizes its portfolio primarily through wholesale distribution to the nation's largest pharmacy chains, wholesalers, and distributors, supplemented by patient assistance programs (the Lomaira 1-2-3 Savings Program at $5–$15/month and the Lo-Cost Access Program at ≤50¢ per tablet) that drive retail pull-through. KVK also pursues contract development and manufacturing services — formulation, Chemistry, Manufacturing & Controls (CMC), and FDA submission readiness — through strategic partnerships such as Sen-Jam Pharmaceutical, where it holds exclusive U.S. manufacturing rights and an equity stake. International expansion is executed via licensing agreements (e.g., Productos Medix for Lomaira in Mexico). Under its Vision 2025 initiative, KVK is constructing a 250,000-square-foot sterile injectable plant in Langhorne, PA and acquired a 461,000-square-foot former Lockheed-Martin complex adjacent to its Newtown headquarters, materially expanding capacity and signaling entry into higher-value sterile injectables.

KVK Tech firmographics

Firmographics
Name
KVK Tech
Legal name
KVK Tech, Inc.
Website
https://kvktech.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
101–250 employees
Short description
KVK Tech is a privately held, Newtown, Pennsylvania-based specialty pharmaceutical manufacturer founded in 2004 that develops, manufactures, and distributes FDA-approved generic medicines and the branded-generic weight-loss product Lomaira domestically across multiple dosage forms and therapeutic areas.
Ownership category
akta.pro rank

Where KVK Tech is headquartered

Location

Headquarters

HQ city
Newtown
HQ country
United States
HQ region
North America

Offices2 records

Markets served

KVK Tech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Others, Infrastructure

Revenue model

  1. Generic Pharmaceutical Product Sales: KVK develops, manufactures, and markets FDA-approved generic pharmaceuticals, generating revenue through the sale of prescription generic medications to pharmacy chains, wholesalers, distributors, and healthcare providers. Revenue is driven by product portfolio breadth across multiple therapeutic areas and dosage forms.
  2. Contract Manufacturing & Development Services: KVK provides formulation development, CMC, and FDA submission readiness services to partner companies such as Sen-Jam Pharmaceutical, including exclusive manufacturing and distribution rights for the United States, generating service and licensing fees.
  3. International Licensing & Royalties: Licensing agreements with international partners such as Medix in Mexico for the manufacture, distribution, and marketing of Lomaira, generating milestone payments and ongoing royalties.

Pricing tiers

ModelBillingPrice
Unit PricingMonthlyLomaira 1-2-3 Savings Program — $5/1x daily, $10/2x daily, $15/3x daily
Unit PricingMonthlyLomaira Lo-Cost Access Program — no more than 50¢ per tablet
Unit PricingMonthlyLomaira no-expiration savings card — $43.50/month for 3 tablets/day

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

KVK Tech product offering

Product offering

Core offering

KVK Tech is a specialty pharmaceutical company that develops, manufactures, and markets FDA-approved generic prescription medications and one branded product (Lomaira) across therapeutic areas including weight management, allergy, muscle relaxation, cardiovascular, and ophthalmology. The company operates fully integrated U.S.-based manufacturing facilities in Pennsylvania, producing oral solids (tablets, capsules), liquids, ointments/creams, nasals, ophthalmics, and injectables. It also provides formulation, CMC, and FDA submission readiness services to development partners.

Product overview

KVK Tech is a specialty pharmaceutical manufacturer offering a portfolio of FDA-approved generic drugs and one branded product (Lomaira). The company manufactures all products in-house at their Pennsylvania facility, covering oral solids (tablets, capsules), oral suspensions, ophthalmic drops, and injectable solutions. The core branded product is Lomaira, an appetite suppressant for weight reduction. The generic portfolio includes medications across therapeutic categories: weight management (phentermine, benzphetamine, phendimetrazine), allergy (chlorpheniramine, promethazine, hydroxyzine), muscle relaxants (cyclobenzaprine), cardiovascular (betaxolol, isoproterenol), neurological/psychiatric (butalbital combinations), urological (oxybutynin), hepatology (ursodiol), nephrology (sodium polystyrene sulfonate), anti-infectives (atovaquone), immunosuppression (cyclosporine), and anti-inflammatory (indomethacin). The company positions itself on quality, affordability, and domestic manufacturing.

Differentiator

Problem solved

Functional benefit

Brands

  • Lomaira: FDA-approved phentermine hydrochloride USP 8mg tablets for weight reduction, the company's flagship branded generic product.

Products and services

  • Lomaira (phentermine hydrochloride USP) 8mg tablets, CIV Prescription weight reduction medication containing phentermine hydrochloride, the most commonly prescribed drug for weight loss. The only strength of phentermine FDA-approved for use up to three times daily before meals, offering flexible dosing for personalized weight-loss treatment plans.
  • Atovaquone Oral Suspension, USP 750 mg/5mL Prescription medication for treating Pneumocystis jiroveci pneumonia (PCP) in teenagers and adults with HIV, and for preventing immunocompromised patients from contracting this type of pneumonia.
  • Betaxolol Tablets, USP Beta-blocker medication for the treatment of hypertension, equivalent to brand Kerlone.
  • Cyclobenzaprine HCl, USP Muscle relaxant medication for relieving muscle spasms, equivalent to brand Flexeril.
  • Cyclosporine Emulsion Ophthalmic Drops 0.05% Authorized generic version of Restasis for treating dry eye disease, providing the same formulation as the brand-name product.
  • Hydroxyzine HCl Tablets Antihistamine medication for anxiety relief and allergic conditions, equivalent to brand Atarax.
  • Phentermine HCl Appetite suppressant medication available in tablet and capsule forms (15mg, 30mg, 37.5mg), equivalent to brand Adipex-P and Fastin.
  • Phendimetrazine Tartrate Tablets Appetite suppressant medication for short-term weight reduction, available in yellow and blue formulations, equivalent to brands Bontril PDM and Plegine.
  • Benzphetamine HCl Tablets Appetite suppressant medication for weight reduction, equivalent to brand Didrex.
  • Butalbital-Acetaminophen-Caffeine Tablets Combination analgesic medication for tension headaches, equivalent to brand Fioricet.
  • Chlorphen-12 / Chlorpheniramine Maleate ER Tablets Extended-release antihistamine for allergy relief, equivalent to brand Chlor-Trimeton 12 Hour.
  • Oxybutynin Chloride Tablets Anticholinergic medication for overactive bladder, equivalent to brand Ditropan.
  • Promethazine HCl Tablets Antihistamine and anti-nausea medication, equivalent to brand Phenergan.
  • Indomethacin Extended Release Capsules NSAID medication for pain, inflammation, and arthritis, equivalent to brand Indocin SR.
  • Isoproterenol HCl Injection Solution Bronchodilator and cardiac stimulant injection, equivalent to brand Isuprel.
  • Sodium Polystyrene Sulfonate (SPS) Potassium-binding resin medication for treating hyperkalemia, available in powder form and unit dose, equivalent to brand Kayexalate.
  • Ursodiol Capsules Bile acid medication for treating gallstones and liver conditions, equivalent to brand Actigall.
  • Contract Development, CMC and Manufacturing Services Pharmaceutical formulation, CMC, and FDA submission readiness services offered to development partners, including exclusive U.S. manufacturing and distribution rights, as demonstrated through the Sen-Jam Pharmaceutical agreement.

Quantifiable outcome

  • Lomaira costs $43.50/month for 3 tablets/day vs. competing treatments: Qsymia ($204.18), Belviq XR ($286.60), Contrave ($264.57)
  • +1 more outcomes

Companies that use KVK Tech

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

KVK Tech technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

KVK Tech partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor and core.

  • TASK ClinicalminorOthers · 11 December 2025TASK Clinical, a global contract research organization, partnered with Sen-Jam Pharmaceutical and will fund two-thirds of the upcoming Phase 3 clinical trial for SJP-001 in exchange for equity. KVK serves as Sen-Jam's corporate venture partner on this program.
  • Sen-Jam PharmaceuticalcoreStrategic or Co-development Partner · 22 March 2022Sen-Jam Pharmaceutical entered a strategic development, manufacturing, distribution, and license agreement with KVK Tech for an oral COVID-19 therapeutic. KVK provides formulation and Chemistry, Manufacturing & Controls (CMC) services while Sen-Jam completes Phase II clinical trials. KVK is making a strategic investment and will have exclusive Manufacturing and Distribution rights for the United States. KVK also serves as KVK's corporate venture partner handling formulation, CMC, and FDA submission readiness for SJP-001 (hangover-prevention therapeutic).
  • Productos Medix S.A. de C.V. (Medix)coreChannel Partner/ Reseller/ Distributor · 14 November 2017KVK entered a strategic licensing agreement with Medix for the manufacture, distribution, and marketing of Lomaira (phentermine hydrochloride USP) 8mg tablets in Mexico. Medix, a leader in pharmaceutical obesity products in Mexico, plans to leverage its extensive physician network and portfolio of over 10 weight-loss products. The agreement includes milestone payments and royalties to KVK. Mexico has the second largest population with obesity in the world.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

KVK Tech competitors and assessment

Company assessment

Direct peers

  • Lannett Company: Lannett is a U.S.-based specialty generic pharmaceutical manufacturer with comparable portfolio breadth across multiple dosage forms and therapeutic categories, similar mid-market scale, and similar reliance on a broad generic portfolio for revenue.
  • Endo Pharmaceuticals: Endo operates a specialty generics and branded generics business with overlapping therapeutic categories (pain, urology, ophthalmology) and a similar U.S. manufacturing footprint. Comparable in serving retail pharmacy chains and wholesalers through a generics-led model.
  • Upsher-Smith Laboratories: Upsher-Smith is a privately held U.S. specialty generics manufacturer of similar size and structure, with comparable FDA-approved generic portfolio and domestic manufacturing focus — a near-direct comparability on business model.
  • Amneal Pharmaceuticals: Amneal is a major U.S. generic pharmaceutical manufacturer with a broad portfolio spanning solid orals, injectables, and ophthalmics — directly comparable to KVK's dosage-form breadth and therapeutic categories.
  • Camber Pharmaceuticals: Camber is a U.S. generics manufacturer specializing in oral solids and other dosage forms; was named alongside KVK in Stanford's methylphenidate quality study, indicating a directly comparable product portfolio and competitive positioning.
  • Apotex Corp. Apotex is a major privately held Canadian-headquartered generic manufacturer with a significant U.S. commercial presence across solid orals and other dosage forms; comparable in business model and customer base to KVK.
  • Patriot Pharmaceuticals: Patriot Pharmaceuticals is a U.S. specialty generics company; named alongside KVK-TECH in the Stanford methylphenidate quality study, indicating a directly comparable generics portfolio in the U.S. market.

Broad incumbents

  • Sandoz (Novartis): Sandoz is one of the world's largest generic pharmaceutical manufacturers; identified alongside KVK in third-party quality rankings. A broader incumbent that competes across most of KVK's therapeutic categories but at vastly greater scale.
  • Sun Pharmaceutical Industries: Sun Pharma is a global specialty generics leader; named alongside KVK in Stanford's methylphenidate quality study, signaling overlapping U.S. generic portfolios and directly competitive positioning.
  • Teva Pharmaceutical Industries: Teva is the largest global generic manufacturer with broad U.S. presence across multiple dosage forms including sterile injectables; a broad incumbent that competes with KVK across most categories and is the dominant force shaping U.S. generic pricing dynamics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

KVK Tech social profiles

Digital presence

KVK Tech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

KVK Tech leadership team

Management profile

Number of profiles

Profiles2 records

KVK Tech subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

KVK Tech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

KVK Tech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KVK Tech

What does KVK Tech do?

KVK Tech is a specialty pharmaceutical company that develops, manufactures, and markets FDA-approved generic prescription medications and one branded product (Lomaira) across therapeutic areas including weight management, allergy, muscle relaxation, cardiovascular, and ophthalmology. The company operates fully integrated U.S.-based manufacturing facilities in Pennsylvania, producing oral solids (tablets, capsules), liquids, ointments/creams, nasals, ophthalmics, and injectables. It also provides formulation, CMC, and FDA submission readiness services to development partners.

Is KVK Tech a public or private company?

KVK Tech is a private company. It is classified as unknown and is currently operating.

When was KVK Tech founded?

KVK Tech was founded in 2004. It employs 101 to 250 people.

Where is KVK Tech based?

KVK Tech is headquartered in Newtown, United States, in the North America region.

How does KVK Tech make money?

Three revenue lines are on record. Generic Pharmaceutical Product Sales are the primary driver. The others are contract Manufacturing & Development Services and international Licensing & Royalties.

Who are KVK Tech's main competitors?

Direct peers on record are Lannett Company, Endo Pharmaceuticals, Upsher-Smith Laboratories, Amneal Pharmaceuticals, Camber Pharmaceuticals, Apotex Corp. and Patriot Pharmaceuticals. Broad incumbents are Sandoz (Novartis), Sun Pharmaceutical Industries and Teva Pharmaceutical Industries.

Does KVK Tech have an API?

No public API is recorded for KVK Tech.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
HNGNKVK Tech Illustrates Why Exceptional Service Is the Ultimate Competitive EdgeKVK Tech, a B2B pharmaceutical supplier, argues that exceptional service provides the ultimate sustainable competitive advantage when product quality and pricing reach parity among competitors. The article outlines three core service strategies: building indispensable trust through reliability and transparency, streamlining regulatory complexity for clients, and fostering long-term loyalty over transactional sales. The author contends that investing in service yields measurable ROI through higher customer retention, increased share of wallet, and stronger brand reputation within the pharmaceutical industry.PR NewswireSen-Jam Pharmaceutical and KVK Tech Complete Final CMC Deliverables for SJP-002C, Paving the Way for Late-Stage Clinical DevelopmentSen-Jam Pharmaceutical and KVK Tech announced the successful completion of final Chemistry, Manufacturing, and Controls (CMC) deliverables for SJP-002C, including the manufacture of three validated submission batches meeting FDA standards. The milestone positions SJP-002C, a novel anti-inflammatory combination drug combining indomethacin and ketotifen, to advance into Phase 2b/3 clinical trials. KVK Tech, a U.S.-based FDA-registered pharmaceutical manufacturer, served as Sen-Jam's exclusive manufacturing partner and holds equity in the company.PR NewswireKVK Tech's Lomaira has successfully completed registration in Mexico through its partner MedixKVK Tech, Inc. announced the successful registration of its prescription weight-loss drug Lomaira (phentermine hydrochloride 8mg tablets) in Mexico through its strategic partnership with Productos Medix S.A. de C.V. Under the licensing agreement, Medix receives rights to manufacture, distribute, and market Lomaira in Mexico, where the country ranks second globally in overweight and obesity prevalence according to WHO data. The expansion represents KVK Tech's effort to address unmet needs in the global obesity epidemic beyond the US market.ContractpharmaSen-Jam Pharmaceutical Enters Strategic Partnership with KVK-TechSen-Jam Pharmaceutical entered a strategic partnership with KVK-Tech for formulation and CMC of its injectable anti-inflammatory SJP-100. The drug targets cytokine storms and aging-related inflammation, with a Phase 2 trial in COVID patients scheduled to complete this summer. Sen-Jam plans to use the work to license manufacturing with international CMOs.PR NewswireKVK Reaches Global Resolution of DOJ LitigationKVK Tech, Inc. announced that it has resolved all matters involving litigation with the U.S. Attorney's Office for the Eastern District of Pennsylvania and the Consumer Protection Branch of the Department of Justice related to charges of distributing adulterated drugs. Under a Deferred Prosecution Agreement, KVK will operate under an independent compliance monitor for three years, while KVK Research has agreed to plead guilty and pay fines. KVK aims to move forward and focus on providing affordable generic pharmaceuticals to the public.PR NewswireKVK Tech Announces Phase II Trial of COVID-19 Oral Therapy is Currently Enrolling in NepalKVK Tech and Sen-Jam Pharmaceuticals announced their collaboration to develop a COVID-19 oral therapy, with Phase II clinical trials currently enrolling participants in Nepal. Under the agreement, KVK Tech will provide formulation, chemistry, manufacturing, and controls (CMC) services, invest strategically in Sen-Jam, and gain exclusive manufacturing and supply rights for the US market, while Sen-Jam will use the CMC package to pursue FDA NDA submission and license the product to contracting manufacturing organizations globally.ContractpharmaSen-Jam Partners with Specialty Pharma ManufacturerSen-Jam Pharmaceutical partnered with KVK Tech to provide formulation and chemistry, manufacturing and controls for its oral COVID-19 therapeutic. KVK will make a strategic investment and hold exclusive U.S. manufacturing and distribution rights, with a finished product expected in 9-12 months.PR NewswireKVK is excited to announce the appointment of Rahul Sareen as Corporate Head of QualityKVK-Tech, Inc. and its affiliate Penn Life Sciences, Inc. announced the appointment of Rahul Sareen as Corporate Head of Quality, effective immediately. Sareen brings over 24 years of pharmaceutical industry experience, most recently serving as VP, Head of Global Quality Operations at Jubilant Pharma, with prior roles at Arrow Laboratories Australia, Watson Pharma, and Sun Pharma. The company CEO expressed confidence that Sareen's quality culture philosophy and experience in remediating Warning Letters and Consent Decree will support sustainable growth and compliance.PR NewswireKVK is pleased to announce the appointment of Ram Kamineni as Chief Operating OfficerKVK-Tech, Inc. has appointed Ram Kamineni as Chief Operating Officer, effective April 8, 2021. Kamineni brings over 38 years of pharmaceutical experience from companies including Jubilant Pharma and Mylan, and is expected to help advance KVK's position in the generics industry. The appointment is part of KVK's strategy to drive sustainable growth and enhance its operations in the healthcare sector.GlobeNewswireKemPharm’s Commercial Partner for APADAZ®, KVK-Tech, Enters into Collaboration Agreement with Sure Med Compliance Focused on Improving Prescribing Education and Compliance for Pain TherapiesKVK-Tech, KemPharm's commercial partner for APADAZ, entered a collaboration with Sure Med Compliance to improve prescribing education and compliance for pain therapies. The program aligns APADAZ with Sure Med's Care Continuity Program, launching initially in Alabama to collect anonymized patient outcome and utilization data. Additional states are expected to follow.